R-Pharm (Russia)

Recent papers from R-Pharm (Russia)

1. Population PK/PD Modeling and Simulation to Predict the Comparative Long-Term Efficacy of Olokizumab in Rheumatoid Arthritis PatientsJournal of Clinical Medicine · 2026
2. The involvement of polymorphisms in the MALAT1 and NEAT1 lncRNA genes in PCOS etiologyEgyptian Journal of Medical Human Genetics · 2026
3. Treatment of Idiopathic Recurrent Pericarditis With GoflikiceptJournal of the American College of Cardiology · 2023
4. Overcoming the Limitations of Protein A: Evolution of Bacterial Protein-Based and Synthetic Affinity Ligands for High-Performance IgG PurificationInternational Journal of Molecular Sciences · 2026
5. Zinc, type 2 diabetes, diabetic kidney disease: focus on hypoxiaFrontiers in Endocrinology · 2026
6. Artificial intelligence advancements in monoclonal antibody development technologyFrontiers in Immunology · 2026
7. Complexes of Zinc(II) Chloride with N-Vinyl-, N-Allyl- and N-Propargylimidazoles: Structural, Theoretical and Biological StudiesPharmaceuticals · 2026
8. Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)Rheumatology and Therapy · 2026
9. The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trialArthritis Research & Therapy · 2025
10. Serum calprotectin in immune-mediated inflammatory rheumatic diseases: a new biomarker of inflammationRheumatology Science and Practice · 2025
11. Compounding of Orphan Drugs as an indicator of systemic obstacles in pharmacy practice: the experience of the Russian FederationPharmacy & Pharmacology · 2025
12. Single-cell RNA profiling suggests goflikicept-mediated immune modulation in idiopathic recurrent pericarditis2025
13. Rheumatological mimickers of HIV infection. Part 1: involvement of the musculoskeletal systemModern Rheumatology Journal · 2025
14. Key results of a multicenter, non-interventional, retrospective study of Ixabepilone therapy in routine clinical practice in patients with locally advanced or metastatic breast cancer after failure of previous therapy NIRMAMedical alphabet · 2025
15. Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodiesModern Rheumatology Journal · 2025
16. Targeting interleukin-1 signaling for renoprotectionFrontiers in Immunology · 2025
17. Depletion-restitution therapy for autoimmune rheumatic diseases. Part 1. Fundamental prerequisites and efficacy of modern treatment technologies: anti-B-cell drugs and CAR-T therapyModern Rheumatology Journal · 2025
18. Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidenceModern Rheumatology Journal · 2025
19. Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.govCurrent Medicinal Chemistry · 2025
20. Pharmacokinetics of pertuzumab biosimilar compared with the original drug in cynomolgus monkeysRussian Journal of Oncology · 2024